Uppsala, Sweden, 2011-09-30 16:36 CEST (GLOBE NEWSWIRE) --
Establishment of Balance Sheet and Income Statement
The Annual General Meeting established the Balance Sheet, Income Statement, Consolidated Accounts and Financial report. It was resolved that share premium reserve SEK 413 374 526, accumulated profit of SEK -63 029 528, and profit for the year SEK -65 998 058, in total SEK 284 346 940, shall be brought forward.
The Board of Directors
The Annual General Meeting discharged the Board of Directors and the Chief Executive Officer from liability for the fiscal year 2010/2011. The AGM made a resolution that the Board shall consist of six regular members without deputies. The AGM re-elected the Board members Bo Cederstrand and Julian Aleksov and newly elected Joel Citron, Martin Nicklasson, Jan Lundberg and Prof. Dr. Horst Domdey. Joel Citron was elected as Chairman of the Board.
Remuneration to the Board and auditors
The AGM established that a member of the Board not employed by the company shall receive remuneration amounting to SEK 250 000. Remuneration to a Board member may, by special agreement with Oasmia Pharmaceutical AB, be invoiced by a company wholly-owned by the Board member. In that case, the invoiced fee will be increased by the amount of social security contributions and VAT. Remuneration to the auditors shall be paid according to bill.
Guidelines for remuneration to senior managers
The AGM approved the guidelines for remuneration to senior managers proposed by the Board.
Nomination committee
The AGM approved the proposal concerning criteria for the selection of a nomination committee for the AGM 2012.
Revision of the Articles of Association
The AGM approved the presented proposal concerning revision of the Articles of Association with respect to new regulations in the Companies Act concerning Notice of General Meeting.
Authorization for the Board to make decisions on issue of new shares and convertible debt instruments
The AGM made a resolution to, in accordance with the proposal by the Board, authorize the Board to make, at one or more occasions, with or without deviation from shareholders’ preferential rights, new share issues for cash payment and/or in kind or offset, or otherwise in accordance with cpt 13 § 7 of the Companies Act, and new issues of convertibles for cash payment and/or in kind or offset, or otherwise in accordance with cpt 15 § 5 of the Companies Act. The total number of shares issued supported by the authorization may not exceed 15 000 000. The total number of convertibles issued supported by the authorization may not exceed more convertibles than enables conversion to 15 000 000 shares.
For more information, please contact:
Julian Aleksov
Chief Executive Officer
Oasmia Pharmaceutical AB
Telephone: +46 (0) 18 50 54 40
E-mail: info@oasmia.com
Maria Lundén, Head of Public Relations, Oasmia Pharmaceutical AB. E-mail: press@oasmia.com Phone: +46 (0) 18 50 54 40. German contacts: Dr. Sönke Knop, Peggy Kropmanns, edicto GmbH, Frankfurt, Germany. E-Mail: oasmia@edicto.de, Phone: +49 (0) 69 90 55 05 51. Information is also available at www.oasmia.com www.nasdaqomxnordic.com www.boerse-frankfurt.de
